- WAC 246-240-201 Use of unsealed radioactive material for which a written directive is required. A licensee may use any unsealed radioactive material identified in WAC 246-240-210 (2)(a)(ii)(G) prepared for medical use and for which a written directive is required that is:
- (1) Obtained from a manufacturer, producer, or preparer licensed under WAC $246-235-100\,(1)$ or equivalent agreement state or NRC requirements; or
- (2) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in WAC 246-240-163 or 246-240-210, or an individual under the supervision of either as specified in WAC 246-240-057; or
- (3) Obtained from and prepared by an agreement state or NRC licensee for use in research in accordance with an investigational new drug protocol accepted by FDA; or
- (4) Prepared by the licensee for use in research in accordance with an investigational new drug protocol accepted by FDA.

[Statutory Authority: RCW 70A.388.040 and 70A.388.110. WSR 22-19-084, \$246-240-201, filed 9/20/22, effective 10/21/22. Statutory Authority: RCW 70.98.050. WSR 13-11-021, \$246-240-201, filed 5/7/13, effective 6/7/13. Statutory Authority: RCW 70.98.050 and 70.98.080. WSR 09-06-003, \$246-240-201, filed 2/18/09, effective 3/21/09. Statutory Authority: RCW 70.98.050. WSR 06-05-019, \$246-240-201, filed 2/6/06, effective 3/9/06.]